1001-5094
2008 Issue 3
..............page:143
..............page:142-143
..............page:141-142
dan bai zhi yu yao wu jie he fang shi de xin fa xian
xie xiao xue
xie xiao xue
..............page:141
CD20 Antagonist Ofatumumab
sun da ning
sun da ning
..............page:140
Anti-arrhythmic Drug Vernadalant HC1
sun da ning
sun da ning
..............page:138-140
..............page:126
..............page:144
kou fu duo ba dian kang ai yao nexavar huo zhun yong yu wu fa shou shu qie chu de gan xi bao ai huan zhe
sun da ning
sun da ning
..............page:143-144
Telaprevir For the Treatment of Hepatitis C
sun da ning
sun da ning
..............page:136-138
Dual Src and Ab1 Kinase Inhibitor Bosutinib
sun da ning
sun da ning
..............page:135-136
The Method of Quality Control for A Formulation of Traditional Chinese Medicine "Xixian Ye"
L(U) Lin-ang;HU Zhi-fang;WANG Yi-ming;LUO Guo-an
L(U) Lin-ang;HU Zhi-fang;WANG Yi-ming;LUO Guo-an
..............page:132-134
Preparation of Solid Lipid Nanoparticles by Emulsification-evaporation Technique
LI Jiang-hui;WANG Bo
LI Jiang-hui;WANG Bo
..............page:127-131
The Factors Relative to Neo-angiogenesis of Pancreatic Adenocarcinoma and Correlated Drugs
WANG Jian;XIE Min
WANG Jian;XIE Min
..............page:121-126
The Pharmacological Activities and Molecular Mechanisms of Action of Neurosteroids
CHEN Hong-kui;HE Ling;LIU Guo-qin;JI Hui
CHEN Hong-kui;HE Ling;LIU Guo-qin;JI Hui
..............page:115-121
Cardiovascular Adenosine Triphosphate-sensitive Potassium (KATP) Channels and Development of Specific Drugs
YANG Ying-ying;YU Feng
YANG Ying-ying;YU Feng
..............page:110-115
mPGES-1: A New Target for Drug Development
GUO Lei;WANG Shu-jun
GUO Lei;WANG Shu-jun
..............page:103-109
Will New Regulations for Follow-on Biologics Be Announced in US?——An Interview with Dr.Y.Philip Zhang
yao xue jin zhan bian ji bu
yao xue jin zhan bian ji bu
..............page:97-102